Targeted therapy for systemic sclerosis: How close are we?

Nature Reviews Rheumatology

Volumn 6, Issue 5, 2010, Pages 269-278

  Ramos Casals, Manuel ^a   Fonollosa Pla, Vicent ^b   Brito Zerón, Pilar ^a   Sisó Almirall, Antoni ^c  

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AMBRISENTAN; AZATHIOPRINE; BOSENTAN; CONNECTIVE TISSUE GROWTH FACTOR; CYCLOPHOSPHAMIDE; DASATINIB; HISTONE DEACETYLASE 7; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ILOPROST; IMATINIB; INFLIXIMAB; METELIMUMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; NIFEDIPINE; PIRFENIDONE; PLACEBO; PLATELET DERIVED GROWTH FACTOR; PREDNISONE; PROSTACYCLIN; RELAXIN; RITUXIMAB; ROSIGLITAZONE; SILDENAFIL; SITAXSENTAN; TADALAFIL; TRANILAST; UNINDEXED DRUG; UNIPROST;

AUTOIMMUNE DISEASE; CLINICAL TRIAL; CONTINUOUS INFUSION; DIGITAL ULCER; DRUG MECHANISM; DRUG MEGADOSE; DRUG TARGETING; DRUG WITHDRAWAL; EVENING DOSAGE; FIBROSING ALVEOLITIS; FIBROSIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL LUNG DISEASE; KELOID; KIDNEY FAILURE; NONHUMAN; PERIPHERAL EDEMA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; REVIEW; SIDE EFFECT; SKIN FIBROSIS; SKIN ULCER; SYSTEMIC SCLEROSIS; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE;

BIOLOGICAL MARKERS; DRUG DELIVERY SYSTEMS; ENDOTHELINS; FIBROSIS; HUMANS; PROGNOSIS; SCLERODERMA, SYSTEMIC;

EID: 77952100021     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2010.48     Document Type: Review

References (124)

1. Gabrielli, A., Avvedimento, E. V. & Krieg, T. Scleroderma. N. Engl. J. Med. 360, 1989-2003 (2009).
2. Charles, C., Clements, P. & Furst, D. E. Systemic sclerosis: hypothesis-driven treatment strategies. Lancet 367, 1683-1691 (2006).
3. Black, C. M., Matucci-Cerinic, M. & Guillevin, L. Progress in systemic sclerosis: a 10-year perspective. Rheumatology (Oxford) 48, iii1-iii2 (2009).
4. Pope, J. E. Connective tissue diseases: new evidence-based guidelines for treating SSc. Nat. Rev. Rheumatol. 5, 300-302 (2009).
5. Boin, F. & wigley, F. Connective tissue diseases: immunosuppressive therapy in SSc: what is the target? Nat. Rev. Rheumatol. 5, 357-358 (2009).
6. Hunzelmann, N. et al. High frequency of corticosteroid and immunosuppressive therapy in patients with systemic sclerosis despite limited evidence for efficacy. Arthritis Res. Ther. 11, R30 (2009).
7. Simeón-Aznar, C. P. et al. Intravenous cyclophosphamide pulse therapy in the treatment of systemic sclerosis-related interstitial lung disease: a long term study. Open Respir. Med. J. 2, 39-45 (2008).
8. van den Hoogen, F. H. et al. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br. J. Rheumatol. 35, 364-372 (1996).
9. Pope, J. E. et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum. 44, 1351-1358 (2001).
10. Nannini, C., west, C. P., Erwin, P. J. & Matteson, E. L. Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthritis Res. Ther. 10, R124 (2008).
11. Tashkin, D. P. et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am. J. Respir. Crit. Care Med. 176, 1026-1034 (2007).
12. Kowal-Bielecka, O. et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann. Rheum. Dis. 68, 620-628 (2009).
13. Airò, P. et al. Intravenous cyclophosphamide for interstitial lung disease associated to systemic sclerosis: results with an 18 month long protocol including a maintenance phase. Clin. Exp. Rheumatol. 25, 293-296 (2007).
14. Pakas, I. et al. Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J. Rheumatol. 29, 298-304 (2002).
15. Yiannopoulos, G. et al. Combination of intravenous pulses of cyclophosphamide and methyprednisolone in patients with systemic sclerosis and interstitial lung disease. Rheumatol. Int. 27, 357-361 (2007).
16. Bérezné, A. et al. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study. J. Rheumatol. 35, 1064-1072 (2008).
17. Hoyles, R. K. et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 54, 3962-3970 (2006).
18. Zamora, A. C. Use of mycophenolate mofetil to treat scleroderma- associated interstitial lung disease. Respir. Med. 102, 150-155 (2008).
19. Vanthuyne, M. et al. A pilot study of mycophenolate mofetil combined to intravenous methylprednisolone pulses and oral low-dose glucocorticoids in severe early systemic sclerosis. Clin. Exp. Rheumatol. 25, 287-292 (2007).
20. Gerbino, A. J., Goss, C. H. & Molitor, J. A. Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest 133, 455-460 (2008).
21. Saketkoo, L. A. & Espinoza, L. R. Experience of mycophenolate mofetil in 10 patients with autoimmune-related interstitial lung disease demonstrates promising Effects. Am. J. Med. Sci. 337, 329-335 (2009).
22. ClinicalTrials. gov: a service of the US National Institutes of Health. Mycophenolate mofetil in systemic sclerosis [online], http://clinicaltrials. gov/ct2/show?term=Mycophenolate+mofetil+ systemic+sclerosis&rank=1 (2010).
23. ClinicalTrials. gov: a service of the US National Institutes of Health. Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II) (SLSII) [online], http://clinicaltrials. gov/ct2/show/NCT00883129?term=Mycophenolate+mofetil+ systemic+sclerosis& rank=4 (2010).
24. Antoniou, K. M. et al. Infliximab therapy in pulmonary fibrosis associated with collagen vascular disease. Clin. Exp. Rheumatol. 25, 23-28 (2007).
25. Denton, C. P. et al. An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis. Ann. Rheum. Dis. 68, 1433-1439 (2009).
26. Ramos-Casals, M. et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 86, 242-251 (2007).
27. Lafyatis, R. et al. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum. 60, 578-583 (2009).
28. Smith, V. P. et al. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann. Rheum. Dis. 69, 193-197 (2010).
29. Cancro, M. P., D'Cruz, D. P. & Khamashta, M. A. The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J. Clin. Invest. 119, 1066-1073 (2009).
30. Tyndall, A., Matucci-Cerinic, M. & Müller-Ladner, U. Future targets in the management of systemic sclerosis. Rheumatology (Oxford) 48, iii49-iii53 (2009).
31. Matsushita, T. et al. Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum. 54, 192-201 (2006).
32. Nevskaya, T. et al. Autologous progenitor cell implantation as a novel therapeutic intervention for ischaemic digits in systemic sclerosis. Rheumatology (Oxford) 48, 61-64 (2009).
33. Nikolov, N. P. & Pavletic, S. Z. Technology insight: hematopoietic stem cell transplantation for systemic rheumatic disease. Nat. Clin. Pract. Rheumatol. 4, 184-191 (2008).
34. Vonk, M. C. et al. Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis. Ann. Rheum. Dis. 67, 98-104 (2008).
35. Nash, R. A. et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood 110, 1388-1396 (2007).
36. van Laar, J. M., Farge, D. & Tyndall, A. Stem cell transplantation: a treatment option for severe systemic sclerosis? Ann. Rheum. Dis. 67, iii35-iii38 (2008).
37. McLaughlin, V. et al. Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis. Rheumatology (Oxford) 48, iii25-iii31 (2009).
38. Sitbon, O. et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J. Am. Coll. Cardiol. 40, 780-788 (2002).
39. McLaughlin, V. V., Shillington, A. & Rich, S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 106, 1477-1482 (2002).
40. Badesch, D. B. et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized controlled trial. Ann. Intern. Med. 132, 425-434 (2000).
41. Barst, R. J. et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur. Respir. J. 28, 1195-1203 (2006).
42. Oudiz, R. J. et al. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest 126, 420-427 (2004).
43. Olschewski, H. et al. Inhaled iloprost for severe pulmonary hypertension. N. Engl. J. Med. 347, 322-329 (2002).
44. wigley, F. M. et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann. Intern. Med. 120, 199-206 (1994).
45. Rademaker, M. et al. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study. BMJ 298, 561-564 (1989).
46. Scorza, R. et al. Effects of longterm cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study. Clin. Exp. Rheumatol. 19, 503-508 (2001).
47. Mayes, M. D. Endothelin and endothelin receptor antagonists in systemic rheumatic disease. Arthritis Rheum. 48, 1190-1199 (2003).
48. Channick, R. N. et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358, 1119-1123 (2001).
49. Rubin, L. J. et al. Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. 346, 896-903 (2002).
50. McLaughlin, V. V. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan. Eur. J. Clin. Invest. 36, 10-15 (2006).
51. williams, M. H. et al. Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart 92, 926-932 (2006).
52. Galie, N. et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study) : a double-blind, randomized controlled trial. Lancet 371, 2093-2100 (2008).
53. Korn, J. H. et al. Digital ulcers in systemic sclerosis. Prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum. 50, 3985-3993 (2004).
54. Seibold, J. R. et al. Bosentan reduces the number of new digital ulcers in patients with systemic sclerosis [abstract]. Ann. Rheum. Dis. 65 (Suppl. 2), 90 (2006).
55. Ramos-Casals, M. et al. Successful treatment of severe Raynaud's phenomenon with bosentan in four patients with systemic sclerosis. Rheumatology (Oxford) 43, 1454-1456 (2004).
56. Funauchi, M. et al. Effects of bosentan on the skin lesions: an observational study from a single center in Japan. Rheumatol. Int. 29, 769-775 (2009).
57. García de la Peña-Lefebvre, P. et al. Long-term experience of bosentan for treating ulcers and healed ulcers in systemic sclerosis patients. Rheumatology (Oxford) 47, 464-466 (2008).
58. Riccardi, M. T. et al. Treatment of digital ulcers in systemtic sclerosis with endothelin-1 receptor antagonist (bosentan) [Italian]. Reumatismo. 59, 135-139 (2007).
59. Hettema, M. E., Zhang, D., Bootsma, H. & Kallenberg, C. G. Bosentan therapy for patients with severe Raynaud's phenomenon in systemic sclerosis. Ann. Rheum. Dis. 66, 1398-1399 (2007).
60. Launay, D. et al. Bosentan for treatment of active digital ulcers in patients with systemic sclerosis [French]. Presse Med. 35, 587-592 (2006).
61. Gore, J. & Silver, R. Oral sildenafil for the treatment of Raynaud's phenomenon and digital ulcers secondary to systemic sclerosis. Ann. Rheum. Dis. 64, 1387 (2005).
62. Fries, R., Shariat K, von wilmowsky, H. & Böhm, M. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation 112, 2980-2985 (2005).
63. Tsifetaki, N. et al. Bosentan for digital ulcers in patients with systemic sclerosis: a prospective 3-year followup study. J. Rheumatol. 36, 1550-1552 (2009).
64. King, T. E. Jr et al. Bosentan for the treatment of idiopathic pulmonary fibrosis: randomized, double-blind, placebo-controlled BUILD 1 study. Am. J. Respir. Crit. Care Med. 177, 75-81 (2008).
65. Seibold, J. R. et al. Bosentan versus placebo in interstitial lung disease secondary to systemic sclerosis (SSc) : the BUILD-2 study [abstract]. Am. J. Respir. Crit. Care Med. 173, A243 (2006).
66. Barst, R. J. et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 169, 441-447 (2004).
67. Barst, R. J. et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J. Am. Coll. Cardiol. 47, 2049-2056 (2006).
68. Girgis, R. E. et al. Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease. Ann. Rheum. Dis. 66, 1467-1472 (2007).
69. Benza, R. L. et al. Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan. J. Heart Lung Transplant. 26, 63-69 (2007).
70. Humbert, M. et al. Results of European postmarketing surveillance of bosentan in pulmonary hypertension. Eur. Respir. J. 30, 338-344 (2007).
71. Galie, N. et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N. Engl. J. Med. 353, 2148-2157 (2005). (Pubitemid 41653106)
72. Badesch, D. B. et al. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J. Rheumatol. 34, 2417-2422 (2007).
73. Rosato, E. et al. Plasma adrenomedullin and endothelin-1 levels are reduced and Raynaud's phenomenon improved by daily tadalafil administration in male patients with systemic sclerosis. J. Biol. Regul. Homeost. Agents 23, 23-29 (2009).
74. Schiopu, E. et al. Randomized placebo-controlled crossover trial of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis. J. Rheumatol. 36, 2264-2268 (2009).
75. Galiè, N. et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 119, 2894-2903 (2009).
76. Denton, C. P., Black, C. M. & Abraham, D. J. Mechanisms and consequences of fibrosis in systemic sclerosis. Nat. Clin. Pract. Rheumatol. 2, 134-144 (2006).
77. Distler, J. H. & Distler, O. Criteria to select molecular targets for anti-fibrotic therapy. Rheumatology (Oxford) 47 (Suppl. 5), v12-v13 (2008).
78. Chung, L. et al. Molecular framework for response to imatinib mesylate in systemic sclerosis. Arthritis Rheum. 60, 584-591 (2009).
79. Pannu, J. et al. Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate. Arthritis Rheum. 58, 2528-2537 (2008).
80. Distler, J. H. et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum. 56, 311-322 (2007).
81. Kantarjian, H. et al. Nilotinib in imatinibresistant CML and Philadelphia chromosomepositive ALL. N. Engl. J. Med. 354, 2542-2551 (2006).
82. Talpaz, M. et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 354, 2531-2541 (2006).
83. Hehlmann, R., Hochhaus, A. & Baccarani, M. Chronic myeloid leukaemia. Lancet 370, 342-350 (2007).
84. Kerkela, R. et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat. Med. 12, 908-916 (2006).
85. Akhmetshina, A. et al. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum. 60, 219-224 (2009).
86. Akhmetshina, A. et al. Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J. 22, 2214-2222 (2008).
87. van Daele, P. L. et al. Is imatinib mesylate a promising drug in systemic sclerosis? Arthritis Rheum. 58, 2549-2552 (2008).
88. Sfikakis, P. P. et al. Imatinib for the treatment of refractory, diffuse systemic sclerosis. Rheumatology (Oxford) 47, 735-737 (2008).
89. Sabnani, I. et al. A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide. Rheumatology (Oxford) 48, 49-52 (2009).
90. Sgonc, R. & Wick, G. Pro-and anti-fibrotic Effects of TGF-beta in scleroderma. Rheumatology (Oxford) 47 (Suppl. 5), v5-v7 (2008).
91. Varga, J. & Pasche, B. Transforming growth factor beta as a therapeutic target in systemic sclerosis. Nat. Rev. Rheumatol. 5, 200-206 (2009).
92. Belvisi, M. G. & Hele, D. J. Peroxisome proliferator-activated receptors as novel targets in lung disease. Chest 134, 152-157 (2008).
93. Wu, M. et al. Rosiglitazone abrogates bleomycininduced scleroderma and blocks profibrotic responses through peroxisome proliferatoractivated receptor-gamma. Am. J. Pathol. 174, 519-533 (2009).
94. Yamada, H. et al. Tranilast inhibits collagen synthesis in normal, scleroderma and keloid fibroblasts at a late passage culture but not at an early passage culture. J. Dermatol. Sci. 9, 45-47 (1995).
95. Li, C. et al. Inhibitory Effect of pravastatin on transforming growth factor beta1-inducible gene h3 expression in a rat model of chronic cyclosporine nephropathy. Am. J. Nephrol. 25, 611-620 (2005).
96. Del Papa, N. et al. Simvastatin reduces endothelial activation and damage but is partially inEffective in inducing endothelial repair in systemic sclerosis. J. Rheumatol. 35, 1323-1328 (2008).
97. Kuwana, M. et al. Increase in circulating endothelial precursors by atorvastatin in patients with systemic sclerosis. Arthritis Rheum. 53, 1946-1951 (2006).
98. Abou-Raya, A. et al. Statins: potentially useful therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers. J. Rheumatol. 35, 1801-1808 (2008).
99. Blagojevic, J. & Matucci-Cerinic, M. Are statins useful for treating vascular involvement in systemic sclerosis? Nat. Clin. Pract. Rheumatol. 5, 70-71 (2009).
100. Denton, C. P. et al. Recombinant human antitransforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial o CAT-192. Arthritis Rheum. 56, 323-333 (2007).
101. Trojanowska, M. Role of PDGF in fibrotic diseases and systemic sclerosis. Rheumatology (Oxford) 47 (Suppl. 5), v2-v4 (2008).
102. Baroni, S. S. et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N. Engl J. Med. 354, 2667-2676 (2006).
103. Classen, J. F. et al. Lack of evidence of stimulatory autoantibodies to platelet-derived growth factor receptor in patients with systemic sclerosis. Arthritis Rheum. 60, 1137-1144 (2009).
104. Ponticos, M. et al. Pivotal role of connective tissue growth factor in lung fibrosis: MAPK-dependent transcriptional activation of type I collagen. Arthritis Rheum. 60, 2142-2155 (2009).
105. Abraham, D. Connective tissue growth factor: growth factor, matricellular organizer, fibrotic biomarker or molecular target for anti-fibrotic therapy in SSc? Rheumatology (Oxford) 47 (Suppl. 5), v8-v9 (2008).
106. Hemmatazad, H. et al. Histone deacetylase 7, a potential target for the antifibrotic treatment of systemic sclerosis. Arthritis Rheum. 60, 1519-1529 (2009).
107. Cantin, A. M., North, S. L., Fells, G. A., Hubbard, R. C. & Crystal, R. G. Oxidant-mediated epithelial cell injury in idiopathic pulmonary fibrosis. J. Clin. Invest. 79, 1665-1673 (1987).
108. Azuma, A. et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 171, 1040-1047 (2005).
109. Levitt, J. & Gould, M. K. Poor choice of primary outcome in a clinical trial of pirfenidone in patients with IPF. Am. J. Respir. Crit. Care Med. 172, 1228-1229 (2005).
110. Nagai, S. et al. Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis. Intern. Med. 41, 1118-1123 (2002).
111. Behr, J., Degenkolb, B., Krombach, F. & Vogelmeier, C. Intracellular glutathione and bronchoalveolar cells in fibrosing alveolitis: Effects of N-acetylcysteine. Eur. Respir. J. 19, 906-911 (2002).
112. Demedts, M. et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med. 353, 2229-2242 (2005).
113. Rosato, E., Borghese, F., Pisarri, S. & Salsano, F. The treatment with N-acetylcysteine of Raynaud's phenomenon and ischemic ulcers therapy in sclerodermic patients: a prospective observational study of 50 patients. Clin. Rheumatol. 28, 1379-1384 (2009).
114. Samuel, C. S., Lekgabe, E. D. & Mookerjee, I. The Effects of relaxin on extracellular matrix remodeling in health and fibrotic disease. Adv. Exp. Med. Biol. 612, 88-103 (2007).
115. Samuel, C. S. et al. The relaxin gene knockout mouse: a model of progressive scleroderma. J. Invest. Dermatol. 125, 692-699 (2005).
116. Giordano, N. et al. Serum relaxin in systemic sclerosis. J. Rheumatol. 32, 2164-2166 (2005).
117. Seibold, J. R. et al. Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 132, 871-879 (2000).
118. Khanna, D. et al. Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, doubleblind, placebo-controlled trial. Arthritis Rheum. 60, 1102-1111 (2009).
119. McLaughlin, V. V. et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 174, 1257-1263 (2006).
120. Humbert, M. et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur. Respir. J. 24, 353-359 (2004). (Pubitemid 39232254)
121. Simonneau, G. et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann. Intern. Med. 149, 521-530 (2008).
122. Gruenig, E. et al. Acute hemodynamic Effects of single-dose sildenafil when added to established bosentan therapy in patients with pulmonary arterial hypertension: results of the COMPASS-1 study. J. Clin. Pharmacol. 49, 1343-1352 (2009).
123. Catapano-Minotti, G., Corsonello, A., Guadalupi, G., Spani, R. & Antonelli-Incalzi, R. Treatment of severe pulmonary hypertension secondary to scleroderma: a three-drug approach. Intern. Med. 47, 511-513 (2008).
124. Corriveau, M. P. et al. The fibrotic phenotype of systemic sclerosis fibroblasts varies with disease duration and severity of skin involvement: reconstitution of skin fibrosis development using a tissue engineering approach. J. Pathol. 217, 534-542 (2009).